But your post raises an interesting question: if a drug regresses cancer through 5 different known modes of action, and a different company holds a patent on each of these modes, will endless litagation prevent the use of the drug in the clinic?
I can't put a finger on it, but panzem and gendicine may work in similar fashion, just different routes and manners. Panzem avoids the gene therapy risk though. HIF-1 and p53 connections....http://caroll.vjf.cnrs.fr/cancergene/CG1232.html see posts 689 and 690 too